Brief: Glaukos Announces US FDA Approval Of NDA Supplement Allowing For Re-Administration Of Idose® Tr
28/01/2026 12:04
Jan 28 (Reuters) - Glaukos Corp GKOS.N: GLAUKOS ANNOUNCES US FDA APPROVAL OF NDA SUPPLEMENT ALLOWING FOR RE-ADMINISTRATION OF IDOSE® TR GLAUKOS CORP - IDOSE TR SHOWS FAVORABLE LONG-TERM CORNEAL SAFETY PROFILE GLAUKOS CORP - IDOSE TR SECOND ADMINISTRATION SAFE AND WELL-TOLERATED Source text: ID:nBw26GLta Further company coverage: GKOS.N ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Glaukos
See all newsGlaukos says late-stage eye disease treatment shows lasting benefits after single dose
Brief: Glaukos Announces Positive Three-Year Epioxa® Results Demonstrating Durable Clinical Outcomes In Keratoconus
US RESEARCH ROUNDUP-Boeing, Twilio, WP Carey
U.S. RESEARCH ROUNDUP-Equinix, Meta, S&P Global
Glaukos Corp reports results for the quarter ended June 30 - Earnings Summary